Impact Highlights



Year in review: 2021

IMPROVING PATIENT ACCESS AND AFFORDABILITY

About 70

price negotiation meetings conducted with manufacturers to secure better prices for selected drugs and medical devices About 30


price negotiation sessions conducted jointly with ALPS and vendors to secure target prices for implants

SUPPORTING GREATER ADOPTION OF CLINICALLY EFFECTIVE AND COST-EFFECTIVE TREATMENTS

Completed

comprehensive drug margin analysis to support the review of public healthcare finance policy 571

implant models listed on Medical Technology Subsidy List (MTSL)



2021 Impact Highlights

DRIVING ADOPTION OF APPROPRIATE CARE

Inaugural "Health Technology Assessment & the Art of Decisionmaking Workshop" to equip healthcare professionals with practical knowledge and skills; full attendance by healthcare professionals from all three healthcare clusters

8 clinical recommendations for appropriate use of chest X-rays and interventions to manage pre-diabetes

3 CPE webinar videos released

2 clinician and patient education resources published

Publication of **ACE Insights**, a biannual e-bulletin for healthcare professionals

2437 person-hours of guided Continuing Professional Education (CPE) provided through one-to-one personalised educational visiting with ACE Clinical Update Service (CUES) and

4 mass professional education meetings

50 collaborations with clinical experts on

ACE Clinical Guidances (ACGs), with 13 formal endorsements from professional bodies

Electronic direct mailers

(eDMs) to reinforce key clinical messages for sustained practice change





EDUCATING PATIENTS ON CLINICALLY EFFECTIVE AND COST-EFFECTIVE CARE

New Consumer Engagement and Education (CEE) workstream established to support patient involvement in ACE's technical work and develop educational resources for patients and carers.

Published Plain English Summaries (PES) and patient factsheets to **encourage shared decision-making** between patients and their doctors



r

3 HTA educational videos released





Shared about advancing patient involvement in healthcare decision-making at a dialogue session attended by

79 patients and carers from

25 patient organisations

ANNUAL WEBSITE METRICS



Website Pageviews

159,597



ACG Pageviews

10,392



Website Visits (sessions)

37,600



Guidance Downloads

18,427

Impact Highlights



2016-2021



More than

\$400 million

cost savings to the healthcare system

Improved access and affordability for selected medicines and medical technologies for

more than

half a million*





Member of









*Estimated annual number of patients who can benefit from the subsidised medicines and medical technologies evaluated by ACE during the first year of subsidy listing

Cumulative Impact Highlights

ACE conducted HTA that informed funding decisions for these treatments that have been listed for subsidy. There have been significant increase in utilisation of these treatments over the years contributing to improved patient health outcomes and cost savings to the healthcare system.

ESTIMATED* IMPACT OVER FIVE YEARS

Non-vitamin K antagonist oral anticoagulants for

treating atrial fibrillation

564

deaths avoided

287

hospitalisations reduced (stroke/ systemic embolism)

572

hospitalisations reduced (intracranial haemorrhage/ gastrointestinal bleed) Sofosbuvir/ velpatasvir for treating chronic

323

hepatitis C

hepatitis C virus associated deaths avoided

250

hepatocellular carcinomas avoided

160

decompensated cirrhosis avoided

Sodium-glucose co-transporter-2 inhibitors for management of type II diabetes

391

deaths avoided

2816

all-cause hospitalisations reduced

Agency for Care Effectiveness

College of Medicine Building 16 College Road, Singapore 169854

Tel (65) 6325 9220 Fax (65) 6224 1677 Email ace_hta@moh.gov.sg Web www.ace-hta.gov.sg